Sequential gemcitabine–docetaxel in BCG-naïve and BCG-failure non–muscle-invasive bladder cancer: a systematic review and meta-analysis - Top-Institutions - MDSpire

Sequential gemcitabine–docetaxel in BCG-naïve and BCG-failure non–muscle-invasive bladder cancer: a systematic review and meta-analysis

  • By

  • Bandar Alhubaishy

  • Ibrahim Beshawri

  • Inam Abulreish

  • Omar Alnajar

  • Hamad Radhi

  • Abduljawad Saleh

  • Saher Alwafi

  • Abdulghafour Halawani

  • July 9, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Iowa Hospitals & Clinics
    University of Iowa Hospitals & Clinics

    Iowa City, Iowa

    Key Differentiators

    • Urology
  • #2

    Johns Hopkins Hospital/Brady Urological Institute
    Johns Hopkins Hospital/Brady Urological Institute

    Baltimore, Maryland

    Key Differentiators

    • Urology
  • #3

    University of Southern California
    University of Southern California

    Los Angeles, California

    Key Differentiators

    • Urology
  • #4

    Charité–Universitätsmedizin Berlin
    Charité–Universitätsmedizin Berlin

    Berlin, Germany

    Key Differentiators

    • Urology
  • #5

    MRC Clinical Trials Unit
    MRC Clinical Trials Unit

    London, United Kingdom

    Key Differentiators

    • Urology

Original Source(s)

Related Content